Loading...

Sandoz Group AG

0SAN.L•LSE
Healthcare
Medical - Pharmaceuticals
£44.55
£-0.18(-0.40%)

Sandoz Group AG (0SAN.L) Stock Overview

Explore Sandoz Group AG’s financial performance, market position, analyst ratings, and future outlook.

Meyka AI Score

B

Score: 66.7/100

Key Financials

Market Cap19.2B
P/E Ratio0.00
EPS (TTM)N/A
ROE0.00%
Fundamental Analysis

AI Price Forecasts

1 Week$44.34
1 Month$45.38
3 Months$44.59
1 Year Target$52.67

0SAN.L Stock Analysis & Investment Overview

Our comprehensive AI-powered analysis of Sandoz Group AG (0SAN.L) provides investors with deep insights into the stock's performance, growth potential, and market positioning. With a Meyka AI Score of B, this stock demonstrates moderate investment characteristics based on our advanced machine learning models.

The current technical analysis reveals key indicators including an RSI of 67.05, suggesting the stock is in a neutral condition. Our forecasting models predict significant price movements, with a 12-month target of $52.67.

Key financial metrics showcase the company's fundamental strength, including a P/E ratio of 0.00 and a market capitalization of 19.2B. These metrics, combined with our AI analysis, provide a comprehensive view for both institutional and retail investors.

Technical Indicators

67.05RSI (14)
0.87MACD
43.34ADX
Stats data is not available for 0SAN.LStats details for 0SAN.L are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.
Analyst Recommendations data is not available for 0SAN.LAnalyst Recommendations details for 0SAN.L are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Company Profile

Sandoz Group AG develops, manufactures, and markets generic pharmaceuticals and biosimilars worldwide. It develops, manufactures, and markets finished dosage forms of small molecule pharmaceuticals to third parties. It also provides protein- or other biotechnology-based products, including biosimilars; and biotechnology manufacturing services; and anti-infectives, such as active pharmaceutical ingredients and intermediates primarily antibiotics. The company was founded in 1886 and is headquartered in Rotkreuz, Switzerland.

CEO

Richard Saynor

Employees

22,049

Headquarters

Suurstoffi 14, Rotkreuz

Founded

2023

Frequently Asked Questions

;